NCT05019950View on ClinicalTrials.gov

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions

Normal Healthy Volunteers

Interventions

DRUG

NIM-1324

Once daily oral tablet

DRUG

Placebo

Once daily oral tablet

Trial Locations (1)

4006

Clinical Site, Herston

Sponsors

Lead Sponsor

NImmune Biopharma

All Listed Sponsors

lead

NImmune Biopharma

INDUSTRY

NCT05019950 - Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers | Biotech Hunter | Biotech Hunter